Prevention and Treatment of Chemotherapy-Induced Alopecia.
alopecia
chemotherapy
hair loss
treatment
Journal
Dermatology practical & conceptual
ISSN: 2160-9381
Titre abrégé: Dermatol Pract Concept
Pays: Austria
ID NLM: 101585990
Informations de publication
Date de publication:
Jul 2020
Jul 2020
Historique:
accepted:
14
04
2020
entrez:
10
7
2020
pubmed:
10
7
2020
medline:
10
7
2020
Statut:
epublish
Résumé
Chemotherapy-induced alopecia (CIA) is one of the most dramatic side effects of chemotherapy. Currently no guidelines are available for its prevention and treatment. Several devices and drugs are used, but results are often disappointing. Our aim is to analyze drugs and devices proposed in the literature for prevention and treatment of CIA induced by cytotoxic drugs and to discuss the evidenced-based opinion. Scalp cooling is the only agent that has been approved by the US Food and Drug Administration for CIA prevention. Minoxidil and bimatoprost should not be used during chemotherapy administration, but they can be used after chemotherapy discontinuation to obtain greater regrowth. Therapy should always be modulated for the patient and no fixed protocol should be used. Trichoscopy and trichogram could be useful tools in supporting this treatment.
Sections du résumé
BACKGROUND
BACKGROUND
Chemotherapy-induced alopecia (CIA) is one of the most dramatic side effects of chemotherapy. Currently no guidelines are available for its prevention and treatment. Several devices and drugs are used, but results are often disappointing.
AIMS
OBJECTIVE
Our aim is to analyze drugs and devices proposed in the literature for prevention and treatment of CIA induced by cytotoxic drugs and to discuss the evidenced-based opinion.
METHODS AND RESULTS
RESULTS
Scalp cooling is the only agent that has been approved by the US Food and Drug Administration for CIA prevention. Minoxidil and bimatoprost should not be used during chemotherapy administration, but they can be used after chemotherapy discontinuation to obtain greater regrowth.
CONCLUSIONS
CONCLUSIONS
Therapy should always be modulated for the patient and no fixed protocol should be used. Trichoscopy and trichogram could be useful tools in supporting this treatment.
Identifiants
pubmed: 32642317
doi: 10.5826/dpc.1003a74
pii: dp1003a74
pmc: PMC7319796
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
e2020074Informations de copyright
©2020 Rossi et al.
Déclaration de conflit d'intérêts
Competing interests: The authors have no conflicts of interest to disclose.
Références
Cancer Treat Rep. 1986 Oct;70(10):1213-4
pubmed: 3756942
J Allergy Clin Immunol. 2006 Nov;118(5):1017-8
pubmed: 17088123
Am J Dermatopathol. 2011 Jun;33(4):345-50
pubmed: 21430504
J Clin Oncol. 2011 Feb 1;29(4):e81-2
pubmed: 21060025
N Engl J Med. 1986 Oct 2;315(14):894-5
pubmed: 3528857
Rev Recent Clin Trials. 2019;14(1):66-71
pubmed: 30457055
Lancet Oncol. 2013 Feb;14(2):e50-9
pubmed: 23369683
Int J Cancer. 2015 Jan 1;136(1):195-203
pubmed: 24811525
Br J Dermatol. 2015;172(5):1384-94
pubmed: 25296533
Clin Chim Acta. 2016 Aug 1;459:53-56
pubmed: 27221206
Science. 2001 Jan 5;291(5501):134-7
pubmed: 11141566
Nutrition. 1996 Jun;12(6):448-9
pubmed: 8875542
Nutrients. 2016 Mar 12;8(3):163
pubmed: 26985904
World J Clin Oncol. 2017 Aug 10;8(4):329-335
pubmed: 28848699
EMBO Mol Med. 2019 Oct;11(10):e11031
pubmed: 31512803
Cancer Res. 1992 Jan 15;52(2):413-5
pubmed: 1728412
J Am Acad Dermatol. 1996 Jul;35(1):74-8
pubmed: 8682968
Am J Med Sci. 1995 Aug;310(2):43-7
pubmed: 7631641
J Cosmet Dermatol. 2019 Apr;18(2):575-580
pubmed: 29992733
Pharm Res. 2006 Nov;23(11):2505-14
pubmed: 16972183
J Dermatol Sci. 2001 Sep;27(1):7-13
pubmed: 11457638
Int J Cancer. 2015 Mar 1;136(5):E442-54
pubmed: 25081068
Ann Oncol. 1994 Oct;5(8):769-70
pubmed: 7826913
Skin Therapy Lett. 2010 Jul-Aug;15(7):5-7
pubmed: 20700552
Ann Otol Rhinol Laryngol. 2020 Feb;129(2):164-169
pubmed: 31581795
Int J Dermatol. 2018 Dec;57(12):1417-1424
pubmed: 29377091
Anticancer Drugs. 1999 Apr;10(4):393-5
pubmed: 10378674
N Engl J Med. 1985 Apr 18;312(16):1060
pubmed: 3982460
FASEB J. 1991 Jul;5(10):2456-8
pubmed: 2065892
J Am Acad Dermatol. 2011 Sep;65(3):624-635
pubmed: 21777992
J Invest Dermatol. 2013 Aug;133(8):2094-7
pubmed: 23474947
Support Care Cancer. 2013 Sep;21(9):2565-73
pubmed: 23636645
Oncologist. 2013;18(7):885-91
pubmed: 23650021
FASEB J. 1992 Feb 1;6(3):911-3
pubmed: 1740239
Ann Oncol. 2005 Mar;16(3):352-8
pubmed: 15642703
Cancer Res. 2000 Sep 15;60(18):5002-6
pubmed: 11016618
Dermatol Ther. 2016 Nov;29(6):424-432
pubmed: 27424565
Eur J Cancer Care (Engl). 2003 Jun;12(2):154-61
pubmed: 12787013